These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 34118395)
61. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874 [TBL] [Abstract][Full Text] [Related]
62. Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration. Ghirelli A; Tosakulwong N; Weigand SD; Clark HM; Ali F; Botha H; Duffy JR; Utianski RL; Buciuc M; Murray ME; Labuzan SA; Spychalla AJ; Pham NTT; Schwarz CG; Senjem ML; Machulda MM; Baker M; Rademakers R; Filippi M; Jack CR; Lowe VJ; Parisi JE; Dickson DW; Josephs KA; Whitwell JL Ann Neurol; 2020 Nov; 88(5):1009-1022. PubMed ID: 32869362 [TBL] [Abstract][Full Text] [Related]
63. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
64. Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer's disease? A 2-year longitudinal study. Lagarde J; Olivieri P; Tonietto M; Rodrigo S; Gervais P; Caillé F; Moussion M; Bottlaender M; Sarazin M Alzheimers Res Ther; 2023 May; 15(1):91. PubMed ID: 37138309 [TBL] [Abstract][Full Text] [Related]
65. Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults. McSweeney M; Pichet Binette A; Meyer PF; Gonneaud J; Bedetti C; Ozlen H; Labonté A; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S; Neurology; 2020 Mar; 94(11):e1190-e1200. PubMed ID: 32015176 [TBL] [Abstract][Full Text] [Related]
66. Differences in gray and white matter Son HJ; Oh JS; Roh JH; Seo SW; Oh M; Lee SJ; Oh SJ; Kim JS Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):357-366. PubMed ID: 30109402 [TBL] [Abstract][Full Text] [Related]
67. Quantitative evaluation of tau PET tracers Chen J; Li Y; Pirraglia E; Okamura N; Rusinek H; de Leon MJ; Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1596-1604. PubMed ID: 29704038 [TBL] [Abstract][Full Text] [Related]
71. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052 [TBL] [Abstract][Full Text] [Related]
72. A multicenter comparison of [ Leuzy A; Pascoal TA; Strandberg O; Insel P; Smith R; Mattsson-Carlgren N; Benedet AL; Cho H; Lyoo CH; La Joie R; Rabinovici GD; Ossenkoppele R; Rosa-Neto P; Hansson O Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2295-2305. PubMed ID: 34041562 [TBL] [Abstract][Full Text] [Related]
73. A comparison of visual assessment and semi-quantification for the diagnostic and prognostic use of [ Mathoux G; Boccalini C; Peretti DE; Arnone A; Ribaldi F; Scheffler M; Frisoni GB; Garibotto V Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1639-1650. PubMed ID: 38182839 [TBL] [Abstract][Full Text] [Related]
74. Pharmacokinetic Evaluation of the Tau PET Radiotracer Wooten DW; Guehl NJ; Verwer EE; Shoup TM; Yokell DL; Zubcevik N; Vasdev N; Zafonte RD; Johnson KA; El Fakhri G; Normandin MD J Nucl Med; 2017 Mar; 58(3):484-491. PubMed ID: 27660144 [No Abstract] [Full Text] [Related]
75. Sex differences in off-target binding using tau positron emission tomography. Smith R; Strandberg O; Leuzy A; Betthauser TJ; Johnson SC; Pereira JB; Hansson O Neuroimage Clin; 2021; 31():102708. PubMed ID: 34091353 [TBL] [Abstract][Full Text] [Related]
76. Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging. Baker SL; Lockhart SN; Price JC; He M; Huesman RH; Schonhaut D; Faria J; Rabinovici G; Jagust WJ J Nucl Med; 2017 Feb; 58(2):332-338. PubMed ID: 27587706 [TBL] [Abstract][Full Text] [Related]
77. Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Lowe VJ; Bruinsma TJ; Wiste HJ; Min HK; Weigand SD; Fang P; Senjem ML; Therneau TM; Boeve BF; Josephs KA; Pandey MK; Murray ME; Kantarci K; Jones DT; Vemuri P; Graff-Radford J; Schwarz CG; Machulda MM; Mielke MM; Roberts RO; Knopman DS; Petersen RC; Jack CR Neurology; 2019 Jul; 93(1):e29-e39. PubMed ID: 31147421 [TBL] [Abstract][Full Text] [Related]